ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1042

Multimorbidity Prevalence in Systemic Lupus Erythematosus: A Population-Based Study

Ali Duarte-Garcia1, Maria Valenzuela-Almada2, Mehmet Hocaoglu3, Jesse Dabit1, Shirley-Ann Osei-Onomah1, Sebastian Vallejo-Ramos1, Kurt Greenlund4, Tina Gunderson1, Kamil Barbour4 and Cynthia Crowson5, 1Mayo Clinic, Rochester, MN, 2Division of Rheumatology, Mayo Clinic, Rochester, MN, 3University of Maryland Medical Center, Midtown Campus, Baltimore, MD, 4Centers for Disease Control, Atlanta, GA, 5Mayo Clinic, Eyota, MN

Meeting: ACR Convergence 2021

Keywords: Epidemiology, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 8, 2021

Title: Epidemiology & Public Health Poster III: Other Rheumatic & Musculoskeletal Diseases (1022–1060)

Session Type: Poster Session C

Session Time: 8:30AM-10:30AM

Background/Purpose: Patients with systemic lupus erythematosus (SLE) have a 3-fold increase in all-cause mortality, compared to the general population. Young patients with SLE are 40 and 60 times more likely to have cardiovascular disease and end-stage renal disease, respectively, and have at least twice the risk for psychiatric comorbidities (e.g., depression) than people of comparable age without SLE (Manzi et al. AJE 1997; Choi et al. Medicine 2019)). These and other chronic conditions have emerged as factors contributing to the excess morbidity and shorter lifespan of patients with SLE. To date, characterization of age-, disease- and treatment-related comorbidities associated with SLE has relied almost exclusively on individual comorbidity assessment. We aimed to compare the prevalence of multimorbidity in SLE patients with the general population.

Methods: Prevalent cases of SLE who met the ACR/EULAR classification criteria and were residents in a 27-county area of the United States on January 1, 2015 were included in the study. SLE patients were age-, sex-, race-, and county-matched to subjects from the same underlying population. Diagnosis codes within a five-year lookback period were used to determine the presence of comorbidities; 2 or more codes at least 30 days apart were used to define a comorbidity. A previously published list of 44 comorbidities was considered (England et al. ARD 2020). SLE and cutaneous lupus codes were excluded from the analysis. We defined multimorbidity as the presence of 2 or more comorbidities (excluding SLE) and substantial multimorbidity as the presence of 5 or more comorbidities. Logistic regression models adjusted for age and sex were performed.

Results: A total of 479 SLE patients were matched to 479 non-SLE comparators. The mean age was 53.2 (SD 16.2) years and 82.3% were female. 86% were non-Hispanic White. Patients with SLE had 5.3 comorbidities compared to 2.9 among non-SLE subjects. Multimorbidity was present in 78.5% SLE vs. 57.8% non-SLE subjects (OR 2.96; 95%CI 2.2-4.0) and substantial multimorbidity was present in 47.6% SLE patients vs. 25.5% non-SLE subjects (OR 3.06; 95%CI 2.28-4.1). Of the 44 conditions examined, 27 were more common in SLE than in non-SLE (Table).

Conclusion: In this population-based cohort, patients with SLE were 3 times as likely to suffer from multimorbidity and substantial multimorbidity compared to the general population. Most comorbidities were overrepresented in SLE patients. These findings highlight the complex care needs of SLE patients.


Disclosures: A. Duarte-Garcia, None; M. Valenzuela-Almada, None; M. Hocaoglu, None; J. Dabit, None; S. Osei-Onomah, None; S. Vallejo-Ramos, None; K. Greenlund, None; T. Gunderson, None; K. Barbour, None; C. Crowson, None.

To cite this abstract in AMA style:

Duarte-Garcia A, Valenzuela-Almada M, Hocaoglu M, Dabit J, Osei-Onomah S, Vallejo-Ramos S, Greenlund K, Gunderson T, Barbour K, Crowson C. Multimorbidity Prevalence in Systemic Lupus Erythematosus: A Population-Based Study [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/multimorbidity-prevalence-in-systemic-lupus-erythematosus-a-population-based-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/multimorbidity-prevalence-in-systemic-lupus-erythematosus-a-population-based-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology